At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 201 enrolled
Drug / intervention
Brincidofovirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Open-Label, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection
In Brief
A Phase 3 clinical trial evaluating Brincidofovir for Adenovirus Infection. Completed, enrolled 201 participants across 33 sites.
Detailed Summary
This was a Phase 3 open-label, non-randomized, multicenter study of oral brincidofovir (BCV) administered twice weekly for the treatment of adenovirus (AdV) infection detected during asymptomatic AdV viremia or during symptomatic AdV infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenovirus Infection
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
First PostedMar 2014
Primary CompletionJun 2016
Study CompletionAug 2016
TodayJul 2026
First PostedMar 14, 2014
Enrollment StartMar 1, 2014
Primary CompletionJun 1, 2016
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.3 years ago
Interventions
Brincidofovirdrug
BCV administered twice weekly, dose depending on weight.